Fig. 3From: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching studySubgroup analysis in the matched cohort. Subgroup analysis for disease progression (A) or death (B). PVT denotes portal vein thrombosisBack to article page